COVID-19 Pneumonia Clinical Trial
— AziAOfficial title:
Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.1 As of April 14, 2020, there have been more than 1.5 million reported cases and 124 000 deaths in more than 200 countries. A recent open-label nonrandomized French study reporte that addition of azithromycin to hydroxychloroquine in 6 patients resulted in numerically superior viral clearance (6/6, 100%) compared with hydroxychloroquine monotherapy (8/14, 57%) or control (2/16, 12.5%). Azithromycin alone has never been tested, whereas azithromycin has immunomodulating and anti-inflammatory properties that could theoretically prevent or limit secondary worsening. Our hypothesis is that azithromycin combined with amoxicillin/clavulanate will be superior to amoxicillin/clavulanate alone to obtain viral clearance at Day 6 in COVID-19 patients with pneumonia and hospitalized in a non-intensive care unit ward.
Status | Not yet recruiting |
Enrollment | 104 |
Est. completion date | July 30, 2020 |
Est. primary completion date | July 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Adult = 18 ans, - Patient with positive SARS-CoV-2 RT-PCR on nasopharyngeal sample at randomization or within the previous 48 hours, - Patient with pneumonia diagnosed by thorax CT-scan or echography, - Patient able to take per os medication, - Written and signed consent of the patient, - Patients affiliated with or benefitting from a social security scheme. Exclusion Criteria: - Patient hospitalized in intensive care unit, - Patient who received more than 24 hours of antibiotic treatment for the ongoing episode, - Chronic renal failure with a Glomerular Filtration Rate < 20ml/min, - Severe hepatic failure, - Severe chronic cardiac insufficiency, - Allergy to macrolides, - Electrocardiogram showing corrected QT prolongation greater than 470 ms in men and 480 ms in women. - Life-threatening presentation expected to lead to possible imminent death (based on provider assessment) |
Country | Name | City | State |
---|---|---|---|
France | Chu Angers | Angers | |
France | CHD Vendée | La Roche-sur-Yon | |
France | CHU Poitiers | Poitiers |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of positive SARS-CoV-2 RT-PCR | Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample | Day 6 | |
Secondary | Rate of positive SARS-CoV-2 RT-PCR | Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal sample | Day 10 | |
Secondary | Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19 | Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 score. Scale ranging from 0 to 8 (0:unifected; 8:dead) | day 6, day 10, and day 30 | |
Secondary | Total duration of antibiotic treatment during the 30 days following inclusion | Total duration of antibiotic treatment during the 30 days following inclusion | 30 days | |
Secondary | Number of all-cause mortality during the 30 days following inclusion | Number of all-cause mortality during the 30 days following inclusion | 30 days | |
Secondary | Number of in-hospital mortality during the 30 days following inclusion | Number of in-hospital mortality during the 30 days following inclusion | 30 days | |
Secondary | Number of patients transferred to intensive care unit during the 30-day follow-up | Number of patients transferred to intensive care unit during the 30-day follow-up | 30 days | |
Secondary | Number of days without mechanical ventilation during the 30 days following inclusion | Number of days without mechanical ventilation during the 30 days following inclusion | 30 days | |
Secondary | adverse events attributable to antibiotic treatment during the 30 days following inclusion | adverse events attributable to antibiotic treatment during the 30 days following inclusion | 30 days | |
Secondary | Hospital length of stay during the 30 days following inclusion | Hospital length of stay during the 30 days following inclusion | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04901676 -
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
|
Phase 3 | |
Not yet recruiting |
NCT04534478 -
Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19
|
Phase 4 | |
Active, not recruiting |
NCT05002517 -
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
|
Phase 3 | |
Completed |
NCT05008393 -
Efficacy of PJS-539 for Adult Patients With COVID-19.
|
Phase 2 | |
Completed |
NCT04569877 -
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
|
Phase 2 | |
Not yet recruiting |
NCT05286255 -
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
|
Phase 1 | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Completed |
NCT06113432 -
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
|
N/A | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Recruiting |
NCT04615429 -
Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19
|
Phase 2 | |
Completed |
NCT05047653 -
RALE Versus CORADS/CT-Severity Score in COVID-19
|
||
Active, not recruiting |
NCT05047016 -
Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY
|
N/A | |
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
Completed |
NCT05504655 -
N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
|
||
Active, not recruiting |
NCT05035524 -
A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19
|
N/A | |
Completed |
NCT05065879 -
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
|
Phase 4 | |
Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
Withdrawn |
NCT04460105 -
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
|
Phase 1 | |
Suspended |
NCT04901689 -
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
|
Phase 3 |